Enteral Docosahexaenoic Acid and Retinopathy of Prematurity: A Randomized Clinical Trial
Bernabe-García M, Villegas-Silva R, Villavicencio-Torres A, Calder PC, Rodríguez-Cruz M, Maldonado-Hernández J, Macías-Loaiza D, López-Alarcón M, Inda-Icaza P, Cruz-Reynoso L
JPEN. Journal of parenteral and enteral nutrition · 46 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Consejo Nacional de Ciencia y Tecnología
- Gobierno
- Instituto Mexicano del Seguro Social
- Gobierno
- Consejo Nacional de Ciencia y Tecnología, Guatemala
- Subvenciones
- Instituto Mexicano del Seguro Social (FIS/IMSS/PROT/G15/1462 from IMSS); Consejo Nacional de Ciencia y Tecnología, Guatemala (Salud‐2015‐2‐261765); Consejo Nacional de Ciencia y Tecnología (Salud‐2015‐2‐261765)
Según 3 financiadores declarados.
Publicación
- Publicado
- 2019-01-06 · JPEN J Parenter Enteral Nutr · vol. 43 · número 7 · págs. 874–882
- Editorial
- Wiley
- Citado
- 55 citas · más que el 94% de estudios similares · 3.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 54 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Retinopathy of Prematurity Studies · Neonatal Respiratory Health Research · Fatty Acid Research and Health
- Palabras clave
- Retinopathy of prematurity, Medicine, Odds ratio, Enteral administration, Randomized controlled trial, Docosahexaenoic acid, Relative risk, Gestational age, Confidence interval, Confounding, Internal medicine, Parenteral nutrition, Incidence (geometry), Birth weight, Neonatal intensive care unit, Pediatrics, Gastroenterology, Pregnancy, Polyunsaturated fatty acid, Fatty acid, Biology
- MeSH
- humans, retinopathy of prematurity, infant, premature, diseases, docosahexaenoic acids, enteral nutrition, parenteral nutrition, logistic models, double-blind method, infant, newborn, infant, low birth weight, infant, premature, female, male
10 autores
- Mariela Bernabé-García🇲🇽 · autor de correspondenciaMexican Social Security Institute; Centro Medico Nacional Siglo XXI
- Raúl Villegas‐Silva🇲🇽Hospital Infantil de México Federico Gómez
- Astrid Villavicencio‐Torres🇲🇽Mexican Social Security Institute; Centro Médico Nacional La Raza
- Philip C. Calder🇬🇧National Health Service; Southampton General Hospital; University Hospital Southampton NHS Foundation Trust; National Institute for Health and Care Research; University of Southampton
- Maricela Rodríguez‐Cruz🇲🇽Mexican Social Security Institute; Centro Medico Nacional Siglo XXI
- Jorge Maldonado‐Hernández🇲🇽Mexican Social Security Institute; Centro Medico Nacional Siglo XXI
- Denisse Macías‐Loaiza🇲🇽Mexican Social Security Institute; Centro Medico Nacional Siglo XXI
- Mardia López‐Alarcón🇲🇽Mexican Social Security Institute; Centro Medico Nacional Siglo XXI
- Patricia Inda Icaza🇲🇽Universidad Anáhuac
- Leonardo Cruz‐Reynoso🇲🇽Mexican Social Security Institute; Centro Médico Nacional La Raza
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Retinopathy of prematurity (ROP) is a disorder of the retina of low-birth-weight preterm infants that potentially leads to blindness. Docosahexaenoic acid (DHA), is protective in experimental models, but its administration as part of parenteral nutrition has shown inconsistent results. We test the effect of enteral DHA to prevent ROP and/or severity and to reduce hospital stay.
Methods
This was a double-blind parallel clinical trial. Preterm infants (n = 110; 55 per group) with birth weight <1500 g but ≥1000 g were recruited in a neonatal intensive care unit. Infants were randomized to receive 75 mg of DHA/kg/d (DHA group) or high oleic sunflower oil (control group) for 14 days by enteral feeding. The effect of DHA was evaluated on any stage of ROP, severe ROP (stage ≥3) incidence, and hospital stay. Groups were compared with relative risk (RR) and 95% confidence interval (CI), Fisher's exact test, Student's t-test, or Mann-Whitney U-test, as appropriate. Logistic regression was applied to adjust for confounders.
Results
There was no difference between the DHA and control groups in ROP risk (RR for DHA = 0.79; 95% CI, 0.49-1.27; P = 0.33). However, patients who received DHA showed lower risk for stage 3 ROP (RR for DHA = 0.66; 95% CI, 0.44-0.99; P = 0.03). After adjusting for confounders, this decreased risk remained significant (adjusted odds ratio = 0.10; 95% CI, 0.011-0.886; P = 0.04). Hospital stay was similar between groups.
Conclusion
Enteral DHA may reduce the incidence of stage 3 ROP.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.